• LAST PRICE
    11.8300
  • TODAY'S CHANGE (%)
    Trending Down-0.3100 (-2.5535%)
  • Bid / Lots
    10.0200/ 2
  • Ask / Lots
    13.2500/ 3
  • Open / Previous Close
    11.7700 / 12.1400
  • Day Range
    Low 11.5000
    High 12.2527
  • 52 Week Range
    Low 5.8500
    High 26.3789
  • Volume
    116,213
    above average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

      Show headlines and story abstract
    • 17 hours ago by Dow Jones
      Companies Mentioned: GAIA, GIFI, NATR, CRVO, SLVR, OWLT, IRMD, ANIX, ZOM

      NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Sidoti Events, LLC, an affiliate of Sidoti & Company, LLC, has released the presentation schedule and weblinks for its two-day November Micro-Cap Conference taking place Wednesday and Thursday, November 13-14, 2024. The presentation schedule is subject to change. Please visit www.sidoti.com/events for the most updated version and webinar links.
    • 18 hours ago by Dow Jones
      Companies Mentioned: CRVO

      (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company's control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company's available cash resources and the availability of additional funds on acceptable terms; the results of the Company's clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on March 29, 2024, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.
    • 18 hours ago by Dow Jones
      Companies Mentioned: CRVO
  • Nov 8, 2024

  • Nov 7, 2024

Peers Headlines